Table 3 Group results: HDC vs RIC and HLA-matched vs HLA-mismatched allo-SCT
RIC ( n =20) | Myeloablative ( n =10) | HLA matched ( n =23) | HLA mismatcheda (n =7) | |||||
|---|---|---|---|---|---|---|---|---|
Parameter | Number | Fraction | Number | Fraction | Number | Fraction | Number | Fraction |
Engraftment | ||||||||
Success | 19 | 0.95 | 10 | 1.00 | 23 | 1.0 | 6 | 0.86 |
Failure | 1 | 0.05 | 0 | 0.00 | 0 | 0.00 | 1 | 0.14 |
Acute GvHD | ||||||||
None | 9 | 0.45 | 8 | 0.80 | 13 | 0.57 | 4 | 0.57 |
Grades I–II | 5 | 0.25 | 0 | 0.00 | 4 | 0.17 | 2 | 0.29 |
Grades III–IV | 6 | 0.30 | 1 | 0.10 | 5 | 0.22 | 1 | 0.14 |
aGvHD but WHO unavailable | 0 | 0.00 | 1 | 0.10 | 1 | 0.04 | 0 | 0.00 |
Chronic GvHD | ||||||||
None | 15 | 0.75 | 4 | 0.40 | 15 | 0.65 | 4 | 0.57 |
Limited | 1 | 0.05 | 2 | 0.20 | 3 | 0.13 | 0 | 0.00 |
Extensive | 0 | 0.00 | 2 | 0.20 | 1 | 0.04 | 1 | 0.14 |
N.a. due to death or last FU ⩽ d100 | 4 | 0.20 | 2 | 0.20 | 4 | 0.17 | 2 | 0.29 |
Outcome | ||||||||
DOC | 1 | 0.05 | 3b | 0.30 | 4b | 0.17 | 0 | 0.00 |
Relapse/DOD | 14 | 0.70 | 5b | 0.50 | 13b | 0.57 | 6 | 0.86 |
Alive in CR at last FU | 5 | 0.25 | 3 | 0.30 | 7 | 0.30 | 1 | 0.14 |
Median FU (months after allo-SCT) | ||||||||
Median | 8 | 12 | 12 | 5 | ||||
Range | 1–62 | 2–119 | 1–119 | 2–62 | ||||
